A recent review of the current R&D Tax Incentive has recommended a maximum cash rebate of $2M of companies with a turnover of less than $20M. AusBiotech would like to gather some qualitative data to assist us in representing the views of the sector.
This survey is aimed at SMEs eligible for the refundable component of the R&D Tax Incentive. Please indicate how this proposed change will impact your company in the nine questions below. If you have any additional documentation to demonstrate how the proposed cap on the R&D Tax Incentive will impact your company, please send to Lorraine Chiroiu, Deputy Chief Executive Officer, AusBiotech, at firstname.lastname@example.org.